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Summary 
Previous studies have accomplished direct lineage reprogramming of many cell types to 
different ones by using defined combinations of transcription factors. Vierbuchen et al. 
showed that the combined ectopic expression of Ascl1, Brn2 and MyT1L can efficiently 
reprogram mouse embryonic fibroblasts (MEFs) into induced neuronal (iN) cells. In another 
study, Ascl1 was characterized as the main driver of this process by its activity as a pioneer 
factor. Previous experiments with Ascl1 single-reprogramming showed that Ascl1 is capable of 
converting MEFs into iN cells, although the reprogrammed neurons show low levels of 
maturity. On the other hand, several reprogramming experiments associated MyT1L with a 
late function by promoting the maturation of iN cells, but not with the capacity to reprogram 
MEFs into iN cells like Ascl1. However, a mechanistic characterization of MyT1L still needed to 
be clarified.  
MyT1L is a member of the MYT1 family, also including MyT1 and MyT3, all zinc-finger 
transcription factors. Recent work from our laboratory showed that MyT1, a paralog of MyT1L, 
acts as a repressor of Notch targets, in neural stem/progenitor cells. One of those identified 
Notch targets was Hes1. In neurogenesis, the Notch pathway induces the activation of the 
Notch downstream effector Hes1. Hes1 functions as a repressor of proneural genes, such as 
Ascl1, as well as their target genes. Similar to the neurogenesis context, it is tempting to 
speculate that in Ascl1-dependent reprogramming Hes1 may be functioning as a repressor of 
Ascl1 targets in MEFs.  
The goal of this work is to investigate the role of MyT1L and the Notch signalling pathway in 
Ascl1-dependent reprogramming of MEFs into iN cells.  
To evaluate Notch activity in MEFs, I compared the expression levels of two Notch targets, 
Hes1 and Hes5, between MEFs and neural stem cells. I show that Hes1 expression in MEFs is 
similar to Hes1 expression in neural stem cells. Hes5 expression is substantially lower in MEFs 
than in neural stem cells. This suggests low Notch activity in MEFs as previous studies identify 
the Hes5 promoter as readout of Notch activation.  
Chemical inhibition of Notch signalling did not alter the Hes1 expression in MEFs. I show 
that the proximal promoter region of Hes1, that mediates regulation by Notch and MyT1 in 
neural stem/progenitor cells, is accessible to transcription factor binding in MEFs. Additionally, 
I show that the Notch effector transcription factor RBPJ binds to the Hes1 proximal promoter 
region. These results in conjunction with the high levels of Hes1 expression in MEFs suggest 
that the Notch pathway is not the main regulator of Hes1 expression in these cells. 
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Work from our laboratory showed that, in transcriptional assays, MyT1 represses the Hes1 
proximal promoter activity, after Notch activation. Here I show that Myt1L can counteract the 
Notch activation of the Hes1 promoter in a transcriptional assay. The Hes1 proximal promoter 
contains three consensus binding sites of the MYT1 family suggesting that MyT1L regulates the 
Hes1 promoter by direct DNA-binding to this region. Using chromatin immunoprecipitation 
assay against a tagged version of Myt1L, I show that MyT1L directly binds to the Hes1 
promoter region two days after being ectopically expressed in MEFs.  
Finally I started the optimization of the Ascl1-depedent reprogramming protocol in MEFs. I 
did observe reprogrammed iN cells after single or combined expression of Ascl1 or 
Ascl1/MyT1L, respectively. However, the percentage of iN cells to total number of cells in 
culture revealed low reprogramming efficiency. Additionally, iN cells observed show low levels 
of maturity in single or combined expression of Ascl1 or Ascl1/MyT1L. Nonetheless, this 
protocol still needs further improvement. 
Overall, my findings indicate that MyT1L binds to DNA in MEFs at early stages of the Ascl1-
dependent reprogramming protocol. The results suggest that MyT1L represses the expression 
of Hes1 in Ascl1-dependent reprogramming and this may lead to the activation of the Ascl1 
targets that promote iN cell maturation.  
Keywords 
Ascl1; Neuronal Reprogramming; Notch signalling pathway; MyT1L; Hes1  
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Sumário 
Vários estudos têm vindo a demonstrar que a reprogramação directa de uma linha celular 
somática para outros tipos celulares pode ser alcançada através da expressão ectópica de 
factores de transcrição. De facto, trabalho desenvolvido por Yamanaka e Takahashi (Takahashi 
and Yamanaka, 2006) demonstrou que a adição de quatro factores de transcrição é suficiente 
para reprogramar fibroblastos em células estaminais pluripotentes. Este estudo estabeleceu 
uma mudança de paradigma na forma como olhamos para o programa de transcrição e a 
plasticidade do genoma da célula. A reprogramação de um tipo celular a partir de células 
estaminais ou somáticas oferece um enorme potencial de aplicações na medicina regenerativa 
e na terapia de doenças. 
A reprogramação de fibroblastos em células neuronais foi alcançada através da adição de 
três factores de transcrição, Brn2, Ascl1 e MyT1L (BAM) (Vierbuchen et al., 2010), em que o 
Ascl1 é o factor de transcrição principal, uma vez que, sozinho, é capaz de converter os 
fibroblastos em neurónios, apesar de apresentarem baixa complexidade morfológica e 
capacidade funcional (Chanda et al., 2014). Curiosamente, Ascl1 funciona como um factor 
pioneiro, sendo capaz de se associar às regiões genómicas, independentemente de se 
encontrarem em locais de cromatina acessível (Raposo et al., 2015; Wapinski et al., 2013).  
O Ascl1 é um factor de transcrição proneural que actua como um regulador da 
diferenciação neuronal no cérebro de mamíferos (Bertrand et al., 2002; Wilkinson et al., 2013). 
No processo de neurogénese, Ascl1 actua principalmente como um activador de transcrição 
sobre uma grande variedade de genes que controlam vários passos da neurogénese, como a 
proliferação das células estaminais neurais/progenitoras, migração celular e crescimento das 
neurites (Borromeo et al., 2014; Castro et al., 2011, 2006). Recentemente, Ascl1 foi 
identificado como um factor de transcrição capaz de modificar a cromatina dos seus genes 
alvos, durante a neurogénese, promovendo a acessibilidade da cromatina para Ascl1 (Raposo 
et al., 2015). 
Durante a neurogénese, o Ascl1 é regulado pela via de sinalização Notch. No 
desenvolvimento do sistema nervoso, a via de sinalização Notch é responsável pela 
manutenção da população de células estaminais neuronais/progenitoras, através da inibição 
da diferenciação neuronal. A proteína Notch activa a expressão de genes repressores da 
neurogénese, dos quais se incluem os genes Hes1 e Hes5. Os genes Hes1/5 actuam como 
repressores da transcrição, sendo um dos seus alvos Asc1. Adicionalmente, resultados 
anteriores do nosso laboratório demonstraram que Hes1 inibe a expressão dos genes alvos de 
Ascl1.  
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Recentemente, estudos realizados no nosso laboratório revelaram que um alvo de Ascl1 
durante a neurogénese, o factor MyT1, tem um papel importante em bloquear a expressão de 
genes alvo de Notch, em particular o Hes1. MyT1 é um factor de transcrição da família MYT1, 
que é composta por outros 2 factores de transcrição: MyT1L e MyT3. Os membros desta 
família são altamente homólogos, particularmente nos domínios proteicos zinc-fingers, 
responsáveis pela ligação ao ADN (Bellefroid et al., 1996; Kim et al., 1997). Todos os membros 
da família MYT1 são expressos no desenvolvimento do sistema nervoso central. Em particular, 
MyT1L é expresso exclusivamente em neurónios e é detectado tanto na neurogénese como na 
fase adulta do organismo (Matsushita et al., 2014). Na reprogramação neuronal, o MyT1L tem 
sido utilizado em vários protocolos para promover um aumento da complexidade morfológica 
e das propriedades electrofisiológicas das células neuronais (Ambasudhan et al., 2011; Pang et 
al., 2011; Vierbuchen et al., 2010; Yoo et al., 2011). Considerando os resultados do nosso 
laboratório em que se demonstrou que MyT1 é um repressor da expressão de Hes1, 
colocámos a hipótese de que MyT1L pudesse também actuar na reprogramação de células 
neuronais como um repressor da expressão de Hes1. 
O trabalho desta dissertação teve como objectivo investigar o papel do MyT1L e da via de 
sinalização Notch na reprogramação de fibroblastos em células neuronais promovida por 
Ascl1.  
Em primeiro lugar analisei a actividade da via de sinalização Notch nos fibroblastos através 
da análise de expressão de dois genes alvos de Notch, Hes1 e Hes5. A expressão destes genes 
foi comparada entre fibroblastos e células NS-5, uma linha de células estaminais neurais com 
elevada actividade da via Notch. Os resultados demonstraram que o nível de expressão de 
Hes1 em fibroblastos e em células NS-5 são semelhantes. No entanto, após inibição química da 
actividade de Notch não observei nenhuma alteração na expressão de Hes1, o que sugere que 
a via sinalização Notch não é a principal reguladora de Hes1 nos fibroblastos. Contrariamente a 
Hes1, a expressão de Hes5 é consideravelmente inferior nos fibroblastos em relação às células 
NS-5. Por outro lado, a inibição química da actividade de Notch levou a uma diminuição da 
actividade da expressão de Hes5, indicando que Hes5 é regulado por Notch em fibroblastos. 
Em segundo lugar, investiguei qual o possível papel de MyT1L na regulação da expressão de 
Hes1 em fibroblastos. Analisei que a região promotora de Hes1, onde anteriormente o nosso 
laboratório demonstrou haver associação de MyT1 em células neurais/progenitoras 
estaminais, se encontra com cromatina acessível à associação de factores de trancrição,  em 
fibroblastos. Também analisei a actividade de MyT1L nessa região promotora de Hes1 através 
de um ensaio de transcrição com a co-expressão de MyT1L e receptor Notch1 activado. Esta 
análise revelou que o MyT1L é um repressor do promotor de Hes1, dependente da activação 
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pela via Notch. Esta região promotora de Hes1 contém três sítios de ligação ao ADN comum à 
família MYT1. De facto, os resultados da imunoprecipitação da cromatina extraída de 
fibroblastos revelaram uma associação do MyT1L ectopicamente expresso na região 
promotora de Hes1.  
Hes1 é um factor repressor da expressão de Ascl1 e dos seus genes alvos. De facto, é 
possível que, no contexto da reprogramação promovida por Ascl1, os níveis de Hes1 endógeno 
possam estar a reprimir a expressão dos genes alvos de Ascl1. Esta repressão de Hes1 pode 
explicar o baixo nível de diferenciação das células neuronais observado na reprogramação com 
apenas sobre-expressão de Ascl1. De facto, MyT1L foi descrito como tendo um papel 
importante no desenvolvimento de características de neurónios morfologicamente complexos. 
Assim é possível que, o MyT1L promova indirectamente a expressão dos genes alvos de Ascl1, 
através da inibição da expressão de Hes1. Deste modo, o protocolo de reprogramação de 
fibroblastos em células neuronais mediado por Ascl1 foi optimizado, com o objectivo de 
investigar a interacção de MyT1L e Hes1, no contexto desta reprogramação. Infelizmente, o 
protocolo não foi estabelecido com sucesso, devido, a uma elevada taxa de morte célular. 
Apesar da elevada morte celular, consegui obter células neuronais, a partir de fibroblastos, 
com apenas a sobre-expressão de Ascl1 em co-expressão com MyT1L. As células neuronais 
obtidas com estas duas condições apresentavam baixos níveis de complexidade morfológica.  
Em conclusão, demonstrei que MyT1L encontra-se associado à região promotora de Hes1 
quando expresso de modo ectópico em fibroblastos e que Myt1L actua como um repressor da 
actividade da região promotora de Hes1 promovida pela activação da via de sinalização Notch. 
A junção destes dois resultados sugere que a inibição da expressão de Hes1 se reflicta nos 
fibroblastos após sobre-expressão de Myt1L. A função de MyT1L pode incluir a repressão da 
expressão de Hes1, promovendo a activação de genes alvos de Ascl1 responsáveis pela 
maturação neuronal. Experiências futuras que demonstrem uma diminuição da expressão de 
Hes1 após a sobre-expressão de MyT1L em fibroblastos devem ser consideradas. 
Adicionalmente, futuras experiências devem também focar-se na descoberta de outros genes 
alvo de MyT1L em fibroblastos que possam ter um papel importante na reprogramação 
promovida por Ascl1 de fibroblastos em neurónios. 
Palavras-chave 
Ascl1; Reprogramação neuronal; Via sinalização Notch; MyT1L; Hes1  
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Introduction 
During mammalian development, intrinsic transcriptional programs driven by transcription 
factors (TFs) are combined with cell extrinsic cues to establish cell identity. Interestingly, some 
TFs are able to active their transcriptional program when ectopically expressed in non-native 
cell types.  Namely, the basic helix-loop-helix (bHLH) TF MyoD induced muscle-specific 
properties in fibroblasts (Davis et al., 1987). More recently, a study by Yamanaka and 
Takahashi (Takahashi and Yamanaka, 2006) demonstrates that the overexpression of four TFs 
(Oct4, c-Myc, Sox2 and Klf4) is sufficient to reprogram mouse embryonic fibroblasts (MEFs) 
into induced pluripotent stem cells (iPSCs).  This study established a paradigm shift in how we 
look at transcriptional programs and genome plasticity. Since then, a variety of other studies 
used the expression of defined combinations of transcription factors to reprogram cells into 
pluripotency or different somatic lineages: Stadfield et al. demonstrated that pancreatic β cells 
can be reprogrammed to iPSCs by overexpressing the same four TFs used by Yamanaka and 
colleagues; also,  fibroblasts have been successfully reprogrammed to a variety of other 
somatic lineages, like cardiomyocytes, hepatocytes and neurons, utilizing TFs specific to each 
lineage (Huang et al., 2011; Ieda et al., 2010; Vierbuchen et al., 2010). Lineage conversion from 
embryonic stem cells (ESCs) and iPSCs or already differentiated somatic cells into other cell 
types, like neuronal cells, attracts vast interest due to its potential application in regenerative 
medicine and in the therapy of developmental diseases (Blanpain et al., 2012; Marchetto and 
Gage, 2012). 
Of specific interest to this dissertation is the first reported study in which MEFs were 
directly reprogrammed into induced neuronal (iN) cells by simultaneous overexpression of 
three TFs, Brn2, Ascl1 and MyT1L (BAM) (Vierbuchen et al., 2010). Other studies followed on 
this reprogramming protocol, albeit with few modifications: conversion of adult human 
fibroblasts to iN cells was achieved by adding NeuroD to the initial BAM set; dopaminergic 
neurons can be induced by expressing the BAM set of factors plus Lmx1a and FoxA2, two 
regulators in dopamine neuron generation (Pang et al., 2011; Pfisterer et al., 2011). More 
recently, Ascl1 was found to be sufficient to reprogram fibroblasts into iN cells, although, these 
iN cells appear  to be more immature than the iN reprogrammed with the full set of BAM 
factors (Chanda et al., 2014). Recent study at the mechanism of iN cells reprogramming by 
BAM set of factors revealed Ascl1 as the main factor that drives the reprogramming process. 
Ascl1 has the ability to function as an “on-target” pioneer factor in MEFs. This means Ascl1 
binds directly to nucleosomal chromatin and to its bona fide targets in neural progenitors 
(Raposo et al., 2015; Wapinski et al., 2013).  
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Ascl1 is a basic Helix-loop-Helix (bHLH) proneural transcription factor that acts as a main 
regulator of neurogenesis in the mammalian brain, alongside other bHLH proneural factors 
expressed in neural stem/progenitor cells (NS/PCs) (Bertrand et al., 2002; Wilkinson et al., 
2013). Proneural factors are both required and sufficient to induce a full program of neuronal 
differentiation. Accordingly, gain-of- and loss-of-function analysis of Ascl1 show, respectively, 
capacity to induce full neuronal differentiation program and neural developmental defects 
associated with reduced neurogenesis (Casarosa et al., 1999; Geoffroy et al., 2009; Raposo et 
al., 2015). The use of genomic approaches has started to elucidate the mechanisms behind 
Ascl1 regulation of neurogenesis. Ascl1 functions as a transcriptional activator (Borromeo et 
al., 2014; Castro et al., 2006; Raposo et al., 2015) over a large number of effector genes that 
control various steps of neurogenesis, such as neuronal fate specification, progenitor 
proliferation, cell migration and neurite outgrowth (Castro et al., 2011). Furthermore, recent 
work revealed that Ascl1 also function as a pioneer factor in its native context, binding closed 
chromatin in some of its targets and promoting changes in the chromatin accessibility at its 
target sites during neurogenesis (Raposo et al., 2015).  
During neurogenesis, Ascl1 is simultaneously regulated and is regulated by the Notch 
signalling pathway. Notch signalling is an evolutionary conserved pathway present in many 
tissues with a wide variety of functions (Andersson et al., 2011). In the developing nervous 
system it is responsible for the process of lateral inhibition, whereby a differentiating neuronal 
progenitor cell transiently inhibits differentiation of surrounding neural stem/progenitors cells 
from undergoing the same fate (Louvi and Artavanis-Tsakonas, 2006). Ascl1 induces Notch 
ligands, such as Delta1, at the transcriptional level. Delta1 binds to the Notch receptor at the 
cell surface triggering intracellular transmembrane proteases to cleave and release the Notch 
Intracellular Domain (NICD). NICD then is translocated to the nucleus where it binds to the 
downstream effector RBPJ. In the absence of Notch activity, RPBJ functions as a repressor at 
promoters of target genes (Castel et al., 2013). Upon Notch activation, RBPJ/ NICD form a 
complex with coactivators that will activate Notch target genes. Amongst these are Hes1 and 
Hes5, two bHLH proteins that function as transcriptional repressors. Hes1/5 can repress 
proneural factors such as  Ascl1 which prevents neuronal differentiation and contributes to the 
maintenance of a pool of neural stem/progenitor cells (Figure 1A) (Hojo et al., 2000; Kageyama 
et al., 2005; Wu et al., 2003). Moreover, unpublished work from our laboratory shows that 
Hes1 additionally represses Ascl1 target genes. Recent studies showed that Notch direct and 
indirect targets, like Hes1 and Ascl1, respectively, are expressed in an oscillatory manner 
(Imayoshi et al., 2013). This results from Hes1 functioning as an intrinsic oscillator, due to its 
ability to repress its own promoter, associated with its short-lived transcript and protein 
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(Hirata et al., 2002). At the same time, Ascl1 oscillates in an out-of-phase manner to Hes1 
oscillation. These two modes of Ascl1 expression, oscillatory or sustained, are associated with 
distinct activities. When expressed in an oscillating mode, Ascl1 promotes cell proliferation. 
When Ascl1 is expressed at constant levels the NS/PCs undergo neuronal differentiation 
(Figure 1B) (Shimojo et al., 2011). What regulates the switch from an oscillatory to sustained 
mode of these TFs expression remains an important question in the field. 
Recent work in our laboratory showed that regulation by Ascl1 of the expression of the 
zinc-finger factor MyT1 may play an important role in this process. MyT1 is a transcriptional 
repressor that regulates a large number of canonical Notch target genes. Importantly, MyT1 
counteracts Notch mediated Hes1 activation (Figure 2A), by a mechanism that requires direct 
DNA binding to three consensus sites at the Hes1 proximal promoter region that partially 
overlap with RBPJ –binding sites (Figure 2B). 
 
 
Figure 1 – Interplay between proneural factor Ascl1 and proneural repressors Hes1/5 at the onset of 
differentiation. (A) Notch signalling is activated through cell-cell interactions between the 
transmembrane proteins Delta-like1 (Dll1) and Notch1 receptor, expressed in neighbouring cells. In 
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differentiating NS/PCs  Ascl1 (as well as other proneural factors) induces the expression of Dll1, which 
activates Notch signalling in the Notch1 receptor-expressing cell. Upon activation, the Notch 
intracellular domain (NICD) is cleaved and translocated into the nucleus where it will form an activator 
complex with RPBJ and induce the expression of downstream genes, such as Hes1/5. Hes1/5 repress the 
expression of Ascl1, thereby inhibiting neuronal differentiation, while the neighbouring cell with Ascl1 
expression is driven to neuronal differentiation. (B) Hes1/5 genes are intrinsic oscillators. The opposing 
interaction between Hes1/5 and Ascl1 proteins results in oscillation of these TFs in an out-of-phase 
pattern. At the onset of neurogenesis, Hes1 expression becomes permanently downregulated and, 
consequently, Ascl1 upregulation is sustained. Figures adapted from (Kageyama et al., 2008) and 
(Vasconcelos and Castro, 2014), respectively. 
MyT1 belongs to a family comprised of 3 members:  MyT1 (NZF2), MyT1L (NZF1) and MyT3 
(NZF3 or st18) that encode structurally related zinc-finger (ZF) transcription factors. Members 
of this family are highly homologous, particularly within the DNA-binding ZF domains (Figure 3) 
(Bellefroid et al., 1996; Kim et al., 1997). All MYT1 family members are expressed throughout 
the mouse developing central nervous system (CNS). Specifically MyT1L is exclusively 
expressed in neurons, throughout neurogenesis and adulthood, and most prominently 
expressed in post-mitotic cells (Matsushita et al., 2014, 2002). Mouse genetics has failed so far 
to identify the function of MYT1 family members during development. No significant defects 
have been reported in the MyT1 null embryo, which may be due to genetic redundancy 
resulting from the concomitant upregulation of MyT1L and MyT3 (Wang et al., 2007). In 
reprogramming, MyT1L overexpression in a variety of neuronal reprogramming protocols has 
been associated with an enhancement of the morphological complexity and 
electrophysiological properties of the induced neurons (Ambasudhan et al., 2011; Pang et al., 
2011; Vierbuchen et al., 2010; Yoo et al., 2011). Various lines of evidence from work conducted 
in our laboratory, including transcriptional assays using promoter-reporter gene constructs, 
implicate MyT1 in counteracting the activation of Notch-dependent activation of Hes1. Given 
that Hes1 has been reportedly expressed in MEFs (Yoshiura et al., 2007), it is tempting to 
speculate that MyT1L may function in Ascl1-dependent reprogramming by repressing Hes1 
expression. 
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Figure 2 – MyT1 regulation of the Hes1 proximal promoter by direct DNA-binding. (A) MyT1 
counteracts Notch activation of Hes1 promoter by direct DNA binding and competition with NICD/RBPJ 
activator complex for DNA binding. (B) Hes1 proximal promoter region contains three MyT1 binding 
sites interspersed and partially overlapping with three RBPJ binding sites. Figure adapted from results 
obtained from our laboratory (Vasconcelos, personal communication). 
The goal of this work is to investigate the role of MyT1L and the Notch signalling pathway in 
Ascl1-dependent reprogramming of MEFs into iN cells. I first determined whether Notch 
signalling is active in MEFs namely its function in regulating Hes1 expression. Secondly, I 
focused on the TF MyT1L and its possible role in regulating Hes1 expression when ectopically 
expressed in MEFs. Thirdly, I attempted to establish the Ascl1-dependent reprogramming 
protocol, with the aim of investigating the interaction of MyT1L and Hes1 in this context. 
 
 
 
 
 
 
Figure 3 – MYT1 family members.  Scheme portrays the structural comparison between members of the 
MYT1 family of transcription factors: MyT1L (1188 amino acis), MyT1 (1127 amino acis) and MyT3 (1045 
amino acids). The blue boxes indicate C2HC-type zinc finger domains. Percentages conservation of 
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various protein domains (set apart by dashed lines) between MyT1L and other members are shown. 
Figure refers to proteins encoded by mouse genes. Figure adapted from (Matsushita et al., 2014). 
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Materials and methods 
1. Animals 
All experiments with NMRI (Charles River) and Transgenic Notch Reporter mice (Jackson 
Laboratories) were carried out upon approval and following the guidelines of the ethics 
committee of Instituto Gulbenkian de Ciência. 
2. Molecular Biology 
2.1. Expression vectors 
The expression vectors are listed on Table 1. 
 
Vector Reference 
pCAG-MyT1L (Kameyama et al., 2011) 
pCAG-MyT1L-HA Generated during this work 
pCAG- MyT1-IRES-GFP (Vasconcelos et al. Unpublished) 
pCAG-acNotch1 Gift from Ryoichiro Kageyama 
p3xFlag-CMV7-NICD1 (Ong et al., 2006)(Addgene #20183) 
pCMV-βgal  
 
2.2. Luciferase reporter vectors 
The expression vectors are listed on Table 2. 
 
Vector Genomic coordinates Reference 
Hes1:Luc chr16:30064977-30065489 
(Nishimura et al., 1998) 
(Addgene #41723) 
2.3. Lentiviral vectors 
The expression vectors are listed on Table 3. 
2.4. Transformation into chemically competent E.coli 
100μL of chemically competent E.coli DH5α were incubated with approximately 500ng of 
vector DNA for 15min on ice. After a 60sec heat shock at 37ºC the bacteria were chilled on ice 
for at least 2min, ∼250μL LB was added. The bacteria were incubated for ∼1h at 37ºC on a 
shaker incubator, subsequently plated on LBAmp plates and placed overnight at 37ºC. 
Table 1 - Expression vectors 
Table 2 – Luciferase reporter vectors 
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2.5. DNA purification 
Plasmids were isolated from E.coli DH5α using Qiagen’s Mini, Midi or Maxi-Prep Kits. PCR-
Products were purified with the Qiagen’s PCR Purification Kit, DNA bands from agarose gels 
were purified with the Qiagen’s Gel Extraction Kit. All steps were performed as recommended 
by the supplier. For phenol-chloroform extraction, one volume of phenol:chloroform:isoamyl 
alcohol 25:24:1 (Sigma-Aldrich) was added. The mixture was vortexed shortly and centrifuged 
for 5min at maximum speed in a tabletop microcentrifuge. Upper phase was recovered and 
1/10 volume of 3M sodium acetate and 0.7 volumes of 100% ethanol (RNase free) were added 
to precipitate DNA. Sample was incubated for 30-60min at RT and centrifuged (10min at RT, 
13000rpm). Supernatant was discarded and the pellet was washed with 70% ethanol. After air 
drying, the pellet was re-suspended in an appropriate volume of RNAse and DNase-free water 
(Sigma-Aldrich). 
2.6. DNA restriction digestion 
For sub-cloning digestions were performed in 50μL total volume with 1-2μg DNA and ∼ 
2units enzyme overnight at 37ºC. 
2.7. Vector dephosphorylation 
Dephosphorylation procedure was performed with purified pre-digested vector and 2μL of 
Antarctic phosphatase (New England Biolabs) to a total volume of 20μL for 15min at 37ºC. 
Heat inactivation of the enzyme was carried out by incubating the mixture for 5min at 65ºC. 
2.8. Ligation 
Ligations were performed with a 10:1 or 3:1 molar ratio insert/vector, for blunt end or 
sticky end ligations, respectively, using the DNA and Takara Long ligation kit (Takara Bio) 
according to manufacturers’ instructions. Samples were incubated at 16ºC overnight and 
transformed the next day. Colonies were selected and inoculated in LB medium with Ampicillin 
Vector Reference 
TetOn-FUW-V5-Ascl1 Gift from Marius Wernig 
TetON-FUW-MyT1L-HA Generated  during this work 
TetON-FUW-MyT1L (Vierbuchen et al., 2010)(Addgene #27152) 
TetON-FUW-eGFP (Vierbuchen et al., 2010)(Addgene #30130) 
TetON-FUW empty Generated during this work 
FUW-M2rtTA (Hockemeyer et al., 2008) (Addgene #20342) 
Table 3 – Lentiviral vectors 
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at 37ºC overnight. To confirm the correct insertion of the insert into the vector, digestion was 
performed at 37ºC for 1.5h and the resulting products were analyzed on a 1% agarose gel. 
2.8.1 .pCAG-Myt1L-HA 
To generate MyT1L tagged C-terminally with influenza hemagglutinin tag (HA tag), an HA 
tag oligonucleotide was inserted into the pCAG-MyT1L by amplifying a fragment of the cDNA 
using an overhang on the Reverse Primer containing the HA tag, STOP codon, one EcoRI site 
and one BglII site (Table 4). The amplified fragment and the pCAG-MyT1L were digested for 
SacI and BglII, and then ligated overnight. Bacteria were transformed and positive colonies 
were screened by digesting the purified DNA with HindIII and EcoRI and by subsequent analysis 
of digestion pattern in agarose gel. Positive colonies were sequenced to confirm the lack of 
mutations. The pCAG-MyT1L-HA has less 9 nucleotides in the MyT1L cDNA than the pCAG-
MyT1L resulting from the strategy employed to remove one EcoRI site present in the MyT1L 
cDNA, near the C-terminal. This was necessary to facilitate further sub-cloning strategies. 
 
Primers Forward Primer Reverse Primer 
MyT1L-HA GCGGACAAAAAGCATTCGAAGTATG 
GATGATAGATCTGAATTCTCAAGCGTAATCTGGTACG
TCGTATGGGTATCCTCTCACAGCCTGCTTTATATTTTC 
  
2.8.2. TetON-FUW Myt1L-HA 
MyT1L-HA was excised from pCAG-MyT1L-HA vector using EcoRI restriction enzyme and 
purified via agarose gel. 
The TetON-FUW V5-Ascl1 was digested with EcoRI and the TetON-FUW backbone was 
purified via agarose gel. 
TetON-FUW backbone and MyT1L-HA fragment were ligated overnight. Bacteria were 
transformed and positive colonies were screened by digesting the purified DNA with StuI and 
by subsequent analysis of the digestion pattern in agarose gel. Positive colonies were 
sequenced to confirm the lack of mutations. 
2.8.3. TetON-FUW empty 
V5-Ascl1 was excised from TetON-FUW V5-Ascl1 with EcoRI. The TetON-FUW backbone was 
purified via agarose gel. TetON-FUW backbone was re-ligated overnight. Bacteria were 
transformed and positive colonies were screened by digesting the purified DNA with EcoRI and 
Table 4 – Primers for Myt1L-HA sub-cloning 
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by subsequent analysis of the digestion pattern in agarose gel. Positive colonies were 
sequenced to confirm the lack of mutations. 
3. Cell culture 
3.1. Cell line generation and maintenance 
Mouse embryonic fibroblasts (MEFs) were isolated from E12.5 embryos under a dissection 
microscope (Nikon). The head, vertebral column (containing the spinal cord), dorsal root 
ganglia and all internal organs were removed and discarded to ensure the removal of all cells 
with neurogenic potential from the cultures. The remaining tissue was manually dissociated 
and incubated 0.25% trypsin (Gibco) for 10-15 min to create a single cell suspension. Cells from 
each embryo were plated onto a T150 flask with MEF media (Dulbecco’s Modified Eagle 
Medium (DMEM)/ High glucose containing 10% fetal bovine serum (FBS) (both from BioWest), 
2mM L-Glutamine and 100U/mL Penicillin/Streptomycin (both from Gibco)). Cells were grown 
at 37 °C until confluent and then split once before being frozen. After thawing cells were 
cultured on T-flasks and allowed to become confluent before being split onto well-plates 
(Corning) for infections using 0.25% trypsin.  
Notch signalling inhibition of MEFs was performed by adding the γ-secretase inhibitor LY-
411575 (Sigma-Aldrich) (Lanz et al., 2004) to the culture to a final concentration of 10nM, for 4 
hours. 
3.2. NS-5, P19 and HEK293T cells culture 
NS-5 cells (Conti et al., 2005) were cultured in mouse Neurocult NSC basal medium 
supplemented with Neurocult NSC proliferation supplement (both from Stem Cell 
Technologies), 100U/mL Penicillin/Streptomycin (Gibco), 10ng/mL EGF (Peprotech), 10ng/mL 
bFGF (Peprotech) and 1µg/mL Laminin (Sigma-Aldrich) in T-flasks or  well-plates.  
P19 embryonic carcinoma cells and human embryonic kidney cells (HEK293T) were 
maintained in DMEM / High glucose supplemented with 10% FBS, 2mM L-Glutamine and 
100U/mL Penicillin/Streptomycin in T-flasks or well-plates.  
3.3. Transfection of P19 and HEK23T cells 
On the previous day, P19 and HEK293T were plated to obtain a75% confluency on the day 
of the transfection. Transfection was carried out with linear polyethylenimine (PEI) (Sigma-
Aldrich) in the proportion of DNA:PEI (w/w) of 1:2.5 for P19 cells and 1:3 for HEK293T cells. 
Total amount of DNA/cm2: 500 ng. Medium was replaced with fresh medium 4-6h after 
transfection. 
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3.4. Lentivirus production and infection of MEF cells 
Replication-incompetent lentiviruses were produced by transient transfection of HEK293T 
cells with TetON-FUW vectors or with FUW-M2rtTA cotransfected with the viral 2nd generation 
packaging vector psPAX2 and the viral envelope vector pVSV-G. Medium was replaced with 
fresh medium 6-8h post transfection. Two days after medium replacement, lentiviral particles 
were concentrated from supernatant by ultracentrifugation at 90000g for 4h at 4 °C and re-
suspended in 0.1% bovine serum albumin (BSA, Promega) in Phosphate-buffered saline (PBS). 
Viral titter was verified after each production by infecting MEFs followed by 
immunofluorescence two days after induction. The number of infected cells was determined 
by visual counting immune-positive cells over all DAPI-positive nuclei.  
MEFs infection was performed with V5-Ascl1, MyT1L-HA or Empty lentivirus, eGFP 
(enhanced green fluorescent protein) lentivirus, and reverse tetracycline transactivator (rtTA) 
lentivirus in a ratio of 1:1:1. Exception was the V5-Ascl1 and Myt1L-HA lentivirus co-infection 
were the eGFP lentivirus was not added to the lentiviral mix. 
4. Dual luciferase reporter gene assay 
P19 cells were seeded into 48-well plates at a density of 70 000 cells/cm2. Cells were 
transiently cotransfected with expression plasmids, firefly luciferase reporter plasmid and 
pCMV-β-galactosidase plasmid as an internal control. 24-36h after transfection, cells were 
lysed with RGA lysis buffer (Potassium phosphate 100μM pH7.8, 1uM EDTA, 10% glycerol, 1% 
Triton X-100, 1μM DTT (All from Sigma-Aldrich) in MilliQ water). Cell lysates were assayed for 
luciferase and β-galactosidase activities. Fold induction represents the values of (luciferase 
activity/β-galactosidase activity) for each condition normalized to control condition. Data are 
presented as mean ± SD of quadruplicate assays. 
5. Protein lysates preparation 
HEK293T cells were transiently transfected with expression constructs using PEI as 
described above. 24h post transfection cells were washed once with PBS and harvested by 
scraping in ice-cold lysis buffer (50mM Tris HCl pH 8.0, 150mM NaCl, 10% Glycerol, 0.1% NP-40 
(all from Sigma-Aldrich), proteinase inhibitors (Roche) and protein quantification was carried 
out using Bradford method. 
6. Western Blot (WB) 
Crude cell lysates samples were diluted in 2x Laemmli buffer (Sigma-Aldrich) and denatured 
for 5min at 95ºC. Samples were separated in 10-12% SDS-PAGE gels and transferred to 
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nitrocellulose membranes (GE Healthcare) using standard procedures. Blots were probed with 
the primary and HRP-conjugated secondary antibodies listed on Table 5.1 and 5.2. 
 
Antigen (species) Working dilution in WB Catalog number Company/Reference 
HA-tag (rabbit) 1:4000 ab9110 Abcam 
α-tubulin 1:10000 T6074 Sigma-Aldrich 
  
 
Antigen (species) Working dilution in WB Company/Source 
Goat Anti-Rabitt IgG (H+L) Poly-HRP 1:5000 Jackson ImmunoResearch 
Donkey Anti-Mouse IgG (H+L) Poly-HRP 1:5000 Jackson ImmunoResearch 
 
7. MEFs reprogramming into iN cells 
MEFs were plated in 24-well plates with non-coated coverslips. Infection was performed, 
24h after plating, in MEF media containing 8µg/mL polybrene (Sigma-Aldrich). After 16-20h in 
media containing lentivirus, the cells were switched into fresh MEF media containing 2µg/mL 
doxycycline (DOX, Sigma-Aldrich) to activate expression of the transduced genes. After 48h 
media was replaced by N3 media (DMEM/F12 w/ Glutamax (Gibco) containing 25µg/mL, 
50µg/mL transferrin, 30nM sodium selenite, 20nM progesterone, 100nM putrescine 
dihydrochloride (All from Sigma-Aldrich) and 100U/mL Penicillin/Streptomycin) or N2B27 
media (DMEM/F12 w/ Glutamax containing 25µg/mL insulin, 1x N2 supplement, 1x B27 
supplement and 100U/mL Penicillin/Streptomycin). Media was changed every 2-3 days for the 
duration of the culture period.  
8. Immunofluorescence 
MEFs were grown on glass coverslips and washed with PBS before fixation with 4% 
formaldehyde for 10min and quenching with 0.1M Tris pH 7.4 for additional 10min. Cells were 
then incubated in 0.3% Triton X-100 in PBS for 10min at room temperature. Cells were blocked 
in a solution of PBS containing 0.1% Tween20 (Sigma-Aldrich) and 10% Normal Goat Serum 
(Cell Signalling Technology) in PBS for 60min (NGS, Gibco) at room temperature. Primary 
antibody and secondary antibodies were diluted in the blocking solution. Primary antibody was 
incubated at 4 °C overnight and secondary antibodies were incubated at room temperature for 
45min. Cells were washed at room temperature three times for 5min with 0.05% Tween20 in 
Table 5.1 – Primary antibodies used in Western blot 
Table 5.2 – Secondary antibodies used in Western blot 
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PBS between primary and secondary staining. Cell nuclei were stained with DAPI (4',6-
diamidino-2-phenylindole; Sigma-Aldrich) (1:10000) before mounting in Aqua Poly/Mount 
(Polysciences). Cells were stained with the primary and secondary antibodies listed on table 
6.1 and 6.2. 
 
Antigen (species) Working dilution in WB Catalog number Company/Reference 
HA-tag (rabbit) 1:1000 ab9110 Abcam 
V5-tag (mouse 1:200 R960-25 Life Technologies 
Tubulin β III (mouse) 1:300 ab5603 Millipore 
Tuj1 (rabbit) 1:1000 802001 BioLegend 
GFP (chicken) 1:1000 06-896 Millipore 
Myt1L (guinea-pig) 1:1000  (Wang et al., 2007) 
 
 
Antigen (species) Working dilution in WB Company/Reference 
Alexa Fluor 488 Goat Anti-Chicken IgG 1:1000 Life Technologies 
Alexa Fluor 488 Goat Anti-mouse IgG 1:1000 Life Technologies 
Alexa Fluor 568 Goat Anti-rabbit IgG 1:1000 Life Technologies 
Alexa Fluor 568 Goat Anti-mouse IgG 1:1000 Life Technologies 
Alexa Fluor 568 Goat Anti-guinea pig IgG 1:1000 Life Technologies 
 
9. Gene expression analysis 
MEFs were plated in 6-well plates (600 000 cells/ well). Notch signalling was inhibited by 
adding the gamma-secretase inhibitor LY to the culture for 4 hours. 
NS-5 cells were plated in 6-well plates (600 000 cells/ well).  
All samples were prepared in triplicate. 
10. RNA extraction 
Total RNA was isolated from cells by using Trizol reagent (Invitrogen) and alcohol 
precipitation. Extracted RNA was purified by DNAse I (Roche) treatment followed by Rneasy 
column purification (RNA CleanUp protocol, Qiagen). EDTA inactivation of DNAse I step was 
omitted. 
Table 6.1 – Primary antibodies used in immunostaining 
Table 6.2 – Secondary antibodies used in immunostaining 
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11. Reverse transcriptase quantitative real-time PCR (RT-
qPCR) 
cDNA was synthetized using the High-Capacity RNA-to-cDNA kit (Applied Biosystems) 
according to the manufacturers’ instruction. An equal amount (500-1000 ng) of total input RNA 
was used on each experiment. Gene expression analysis by quantitative real-time PCR using 
PerfeCTa SYBR Green FastMix, ROX (Quanta Biosciences) was carried out according to the 
manufacturers’ instructions on the CFX384 Touch™ Real-Time PCR Detection System (Biorad). 
The primers used are listed on Table 7. Triplicates of each biological replicate were used in the 
RT-qPCR. Values are normalized to β-actin expression levels and to untreated sample. Starting 
Quantity was calculated using the CFX Manager™ software (Biorad). Results are shown as 
mean ± SD of triplicate assays.  
 
Gene Forward Primer Reverse Primer 
β-actin CTAAGGCCAACCGTGAAAAG ACCAGAGGCATAGGGACA 
GAPDH GGGTTCCTATAAATACGGACTGC CCATTTTGTCTACGGGACGA 
Hes1 TGAAGGATTCCAAAATAAAATTCTCTGGG CGCCTCTTCTCCTGATAGGCTTTGATGAC 
Hes5  AAGTACCGTGGCGGTGGAGAT CGCTGGAAGTGGTAAAGCAGC 
Notch1 CTGGACCCCATGGACATC GGATGACTGCACACATTGC 
 
12. ChIP-qPCR 
12.1. Chromatin isolation from MEFs cultures 
Cells were washed with PBS and fixed in PBS-Mg (1mM MgCl2 in PBS) containing 2mM 
Disuccinimidyl-glutarate (DSG) (Sigma-Aldrich) for 45min at RT on a rocking platform. Cells 
were washed with PBS and fixed in PBS-Mg with 1% formaldehyde (Sigma-Aldrich) for 10min at 
RT on a rocking platform. Crosslinking was quenched by addition of glycine to a final 
concentration of 125mM for 5min at RT. Subsequently, cells were washed twice in PBS and 
harvested by scraping in 1mg/mL BSA PBS (with proteinase inhibitors (Roche)). After a low 
speed centrifugation, cell pellets were re-suspended in SDS lysis buffer (1% SDS (Sigma-
Aldrich), 10mM EDTA, 50mM Tris pH 8.0, Proteinase inhibitors) and incubated for, at least, 
10min at +4 ᵒC. Chromatin was transferred to non-sticky eppendorfs (Ambion) and sheared by 
sonication using a Bioruptor sonicator (Diagenode) at high power settings in 30s ON/OFF cycles 
at +4 ᵒC. Centrifugation at 14 000rpm for 10min at +4 ᵒC allowed the precipitation of cell 
debris and the soluble chromatin fraction on the supernatant was collected. Chromatins were 
Table 7 – Primers used in expression-qPCR 
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snap-frozen in liquid nitrogen and stored at -80 ᵒC. To verify the efficiency of the sonication, an 
aliquot of chromatin was subjected to reverse crosslinking and Proteinase K (0.1mg/mL, 
Roche) digestion followed by DNA purification by phenol-chloroform extraction. Fragment size 
was determined by agarose gel electrophoresis. 
12.2. Chromatin immunoprecipitation 
Reactions were performed in non-sticky eppendorfs (Ambion) using 50-100μg of chromatin 
and 50μL of magnetic beads and the appropriate antibody in each ChIP reaction (Table 8). As a 
negative control, an IP without antibody was run in parallel. Beads were washed 5 times with 
washing buffers followed by one wash with TE (10mM Tris-HCl pH 8.0, 1mM EDTA) wash. 
Bound chromatin was eluted by incubation of the beads with elution buffer (50mM Tris-HCl pH 
8.0, 10mM EDTA, 1% SDS) for 12min at 65 ᵒC. Proteins were digested by Proteinase K 
(0.1mg/mL) (Roche) for 2h at 42ºC and crosslinking was reverted overnight at 65 ᵒC. The DNA 
was purified performing one phenol/chloroform extraction and one chloroform:isoamyl 
alcohol 25:24:1 extraction followed by isopropanol precipitation and centrifugation for 20min 
at 14 000rpm, +4 ᵒC. Glycogen (40μg) (Sigma-Aldrich) to facilitate the visualization of the pellet 
after centrifugation. For anti-RBPJ ChIP, Protein G Dynabeads (Invitrogen), high salt IP buffer 
(20mM HEPES pH 8.0, 2M NaCl, 2mM EDTA, 0.1% Sodium deoxycholate (NaDOC, Sigma-
Aldrich), 1% Triton X-100,1mg/mL BSA, Proteinase inhibitors (Roche)) were used. Samples 
were subject to 3 washes with Reduced SDS Washing Buffer (50mM HEPES pH 7.6, 150mM 
NaCl, 2mM EDTA, 0.1% NaDOC (Sigma-Aldrich), 1% Triton X-100, 0.1% SDS), 1 wash with 
Reduced SDS Washign buffer high salt (Reduced SDS Washign buffer with 1M NaCl), 2 washes 
with LiCl buffer (10mM Tris HCl pH 8.0, 250mM LiCl, 1mM EDTA, 0.5% NP-40, 0.5% NaDOC) 
and 1 wash with TE buffer (10mM Tris HCL pH 8.0, 1mM EDTA).  
For anti-HA ChIP, Protein G Dynabeads (Invitrogen) and high salt IP buffer were used. 
Sampels were subject to one wash with low-salt buffer (20mM Tris HCl pH 8.0, 150mM NaCl, 
2mM EDTA, 1% Triton X-100, 0.1% SDS), one wash with high-salt buffer (20mM Tris HCl pH 8.0, 
500mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% SDS) and one wash with LiCl buffer (10mM 
Tris HCl pH 8.0, 1mM EDTA, 1% NP-40, 1% NaDOC, 250mM LiCl). 
 
Antigen (Species) Volume used in ChIP Catalog number Company / Reference 
RBPJ (rabbit) 7.5µL/50µL beads 5313 Cell signalling Technology 
HA-tag (rabbit) 3µL/50µL beads ab9110 Abcam 
Table 8 – Antibodies used in ChIP 
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The purified DNA retrieved from the ChIP was analyzed by qPCR (primers listed on Table 9) 
using the standard mix protocol of PerfeCTa SYBR Green FastMix, ROX (Quanta Biosciences). 
Reaction was run under the following cycling conditions: 1 cycle (50ºC/ 2min; 95ºC/ 3min); 40 
cycles (95ºC/ 15sec; 60ºC/ 1min); 1 cycle (95ºC/ 15sec; 60ºC/ 15sec; 95ºC/ 15sec) in ABI 
7900HT (Applied Biosystems). Quantities of immmunoprecipitated DNA were calculated by 
comparison with a standard curve generated by serial dilutions of input DNA. Results are 
shown as mean ± SD of fraction of input chromatin for triplicate assays. Open reading frames 
(ORFs) were used as negative control regions. 
 
Primers Forward Primer Reverse Primer 
Hes1 ORF (ORF1) CACTTTCTGCCTTCTGTGGA AGAGGATGGAGGAGTCATGG 
Dll1 ORF (ORF2) GTCTCAGGACCTTCACAGTAG GAGCAACCTTCTCCGTAGTAG 
Fbxw7 ORF (ORF2) CTCGTCACATTGGAGAGTGG CAGGAGCTTGGTTTCCTCAG 
Hes1 GGGAAAGAAAGTTTGGGAAGT GTTATCAGCACCAGCTCCAG 
Notch1 AAGTGGGAGGGGATTAAGGT CAGGTATTGGGTGTCGGAGT 
12.3. FAIRE-qPCR 
Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE) was performed as previous 
described (Giresi et al., 2007). Chromatin preparation was performed after a single fixation 
with 1% formaldehyde (Sigma-Aldrich). Three rounds of phenol/chloroform extraction were 
followed by isopropanol precipitation of the DNA. Quantification of genomic regions was done 
using a standard curve generated with de-cross-linked input chromatin by qPCR as above.  
The purified DNA retrieved from the FAIRE was analyzed by qPCR (primers listed on Table 
10) using the standard mix protocol of PerfeCTa SYBR Green FastMix, ROX (Quanta 
Biosciences). Reaction was run under the following cycling conditions: 1 cycle (50ºC/ 2min; 
95ºC/ 3min); 40 cycles (95ºC/ 15sec; 60ºC/ 1min); 1 cycle (95ºC/ 15sec; 60ºC/ 15sec; 95ºC/ 
15sec) in the CFX384 Touch™ Real-Time PCR Detection System (Biorad). Quantities of 
immmunoprecipitated DNA were calculated by comparison with a standard curve generated 
by serial dilutions of input DNA. Results are shown as mean ± SD of fraction of input chromatin 
for triplicate assays. ORFs were used as negative control regions. 
 
 
 
Table 9 – Primers used in ChIP-qPCR 
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Primers Forward Primer Reverse Primer 
Hes1 ORF (ORF1) CACTTTCTGCCTTCTGTGGA AGAGGATGGAGGAGTCATGG 
Dll1 ORF (ORF2) GTCTCAGGACCTTCACAGTAG GAGCAACCTTCTCCGTAGTAG 
Hes1 GGGAAAGAAAGTTTGGGAAGT GTTATCAGCACCAGCTCCAG 
Table 10 – Primers used in FAIRE-qPCR 
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Results 
1. Investigating the Notch signalling activity in Mouse 
Embryonic Fibroblasts (MEFs) 
1.1. Generation of MEFs from Transgenic Notch Reporter (TNR) mice  
Notch signalling activity in mouse embryonic fibroblasts (MEFs) has been implicated with 
promoting cell cycle arrest and apoptosis (Ishikawa et al., 2008; Liu et al., 2012), but it is still 
unclear to which extent the endogenous Notch pathway is active in this cellular context. To 
study the activity of the endogenous Notch signalling I made use of the Transgenic Reporter 
mice line (TNR). These mice express Enhanced Green Fluorescent protein (eGFP) under the 
control of 4 tandem copies of the RBPJ binding site consensus sequence. When Notch is 
activated, the NICD-RBPJ complex forms and activates eGFP expression (Figure 4B). I therefore 
isolated MEFs from TNR mice and established TNR-MEF cell cultures (Figure 4A).  
Since cell contact promotes the activation of the canonical Notch signalling pathway, MEFs 
were cultured at different densities (120, 240, 360 cells/µL) and tested for the levels of eGFP 
expression by immunostaining against eGFP. However, eGFP staining was not detected in any 
of the cultures tested (data not shown).  
 
 
 
 
 
 
 
 
 
 
Figure 4 – MEFs production protocol and TNR mice Notch activity reporter. (A) Scheme depicting the 
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general production of mouse embryonic fibroblasts (MEFs) and live imaging of wild-type MEFs culture 
from 3rd passage (P3). (B) Transgenic Notch Reporter (TNR) present in TNR mice, in which four tandem 
RBPJ binding sites mediate Notch signalling of the expression of eGFP. 
Although this could be indicative of no/low Notch signalling activity, a more definite 
conclusion will require testing the functionality of the transgenic system by ectopic expression 
of Notch activators in TNR MEF cultures. 
1.2. Evidence for very low levels of Notch signalling in MEFs 
Given that the reporter failed to provide an indication of Notch activity in MEFs, it is 
possible that Notch activity is much lower in MEFs than in other cell types. To investigate this, I 
compared the mRNA levels of known Notch targets in cultured NS/PCs (NS-5 cells), known to 
have high levels of Notch activity, with the correspondent levels in wild type MEFs. In fact, the 
expression analysis through qPCR quantification shows that Notch targets Hes1 and Notch1 are 
expressed at the same order of magnitude in wild type MEFs and NS-5 cells in culture. This is 
equally observable in the housekeeping genes β-Actin and GAPDH. In contrast, the mRNA 
levels for Hes5, a target that is widely used as a read-out of Notch signalling activity (Basak and 
Taylor, 2007; Lugert et al., 2010), is 1000 times lower in wild type MEFs when compared to 
those measured for NS-5 cells in culture (Figure 5A). To assess for Notch activity dependency, 
wild type MEFs were incubated with an inhibitor of Notch signalling, the γ-secretase inhibitor 
LY-411575 (herein referred to as LY). Levels of expression of Hes1 and Hes5 were measured by 
qPCR and compared between two conditions, with and without LY. While Hes5 expression is 
downregulated 2-fold in presence of LY (Figure 5B), no alteration of Hes1 expression is 
detected (Figure 5C).Overall, these results suggest that Hes5 is expressed at very low levels in 
MEFs and Hes1 is highly expressed in MEFs, with no indication of Notch signalling being 
involved.  
1.3. RBPJ binds to the Hes1 proximal promoter in MEFs 
The previous results show that Hes1 and Hes5 have different expression levels in MEFs. To 
determine if the expression levels are a result from different accessibility to their promoter 
region I performed a FAIRE-qPCR of the proximal promoter regions of Hes1 and Hes5 (Figure 
6A). High enrichment for nucleosome-depleted DNA of the Hes1 proximal promoter region 
was found. The contrary was observed for the Hes5 proximal promoter region (Figure 6B). The 
two promoter regions where compared to two negative control regions. The results 
demonstrate that difference in expression of Hes1 and Hes5 is related to differences in their 
respective promoter regions accessibility.  
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Figure 5 – Hes1, but not Hes5, is expressed in MEFs. (A) Comparative expression analysis of Hes1, Hes5, 
Notch1, GAPDH and β-Actin in MEFs and NS-5 cells; (B) Gene expression analysis of Hes5 and Hes1 in 
MEFs before (-LY) or after (+LY) treatment with ɣ-secretase inhibitor LY-411575 by expression real-time 
PCR. Mean ± SD of triplicate assays are shown. 
In NS/PCs, Hes1 is regulated by Notch signalling through the activity of RPBJ-NICD activator 
complex. RBPJ regulates Hes1 through binding to three consensus binding sequences located 
in Hes1 proximal promoter region (Figure 2B) (Iso et al., 2003).  To determine if endogenous 
RBPJ binds to the Hes1 proximal promoter region, I performed chromatin immunoprecipitation 
(ChIP) with antibody against RBPJ, followed by qPCR (Figure 7A). Different sonication times 
(10, 20 and 30minutes) were initially tested for the chromatin extracted from wild type MEF 
cultures, indicating an ideal sonication time of 30 minutes for chromatin fragments ranging in 
size between 100-400bp (Figure 7B). ChIP-qPCR results demonstrate a strong enrichment of 
RBPJ to the Hes1 proximal promoter region, as compared with the negative control regions 
(Figure 7C).  
Overall, both FAIRE- and ChIP-qPCR results are consistent with the proximal promoter 
region of Hes1 being accessible for transcription factor binding. 
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2. MyT1L counteracts Notch activation of the Hes1 
promoter by direct DNA-binding 
2.1. Generation of a tagged version of MyT1L 
With the aim of studying binding of MyT1L to its putative target genes in MEFs by ChIP, I 
generated a tagged version of MyT1L to increase ChIP efficiency. The influenza hemagglutinin 
tag (HA tag) was fused to MyT1L C-terminus. This was performed by PCR amplification of a 
fragment using pCAG-Myt1L as a template (Figure 8A). The amplification also included an 
EcoRI site, a step required for subsequent sub-cloning in to a lentiviral vector. To confirm 
expression, HEK293T cells were transfected with two different clones of pCAG-MyT1L-HA. 
Expression of both constructs was confirmed in a western blot by the presence of a protein 
corresponding to the expected molecular weight of approximately 133kDA (Figure 8B). 
 
 
 
 
 
 
 
 
 
 
 
(Figure continues next page) 
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Figure 6– Chromatin is accessible in the Hes1 proximal promoter region in MEFs. (A) Scheme depicting 
of the FAIRE protocol followed by real-time PCR. (B) Analysis of the DNA fragments size by 
electrophoresis after sonication of the chromatin. Blue rectangle indicates chromatin fragments. (C) 
Quantification of nucleosome-depleted chromatin at Hes1 and Hes5 proximal promoter region by FAIRE-
qPCR using chromatin extracted from MEFS derived from E12.5 wild-type mice. Two negative control 
regions within the gene open reading frame (ORF) were tested (ORF1-Hes1; ORF2-Dll1). Mean ± SD of 
triplicate assays are shown. 
In order to assess the functionality of the fusion protein, a Reporter Gene Assay (RGA) was 
performed in transfected P19 cells, using a construct containing the luciferase gene under the 
regulation of the Hes1 proximal promoter region. This vector was co-transfected with 
expression vectors encoding activated Notch1 (aN1) (a dominant active version of the Notch1 
receptor), MyT1L wild type (MyT1L-WT) and MyT1L-HA. As expected, aN1 upregulates the 
activity of the Hes1 promoter by 20-fold (Figure 8C), while in presence of either MyT1L species 
this upregulation is significantly reduced to less than 5-fold. This result indicates that the 
MyT1L-HA construct is able to downregulate the Hes1 promoter to the same extent of the 
MyT1L-WT.  
Overall, these experiments indicate that the MyT1L-HA fusion construct is functional and 
expressed with the correct molecular weight. 
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Figure 7 – MEFs have endogenous RBPJ binding to the Hes1 proximal promoter region. (A) Scheme 
depicting the chromatin immunoprecipitation (ChIP) protocol followed by real-time PCR. (B) Analysis of 
the DNA fragments size (blue rectangles) by electrophoresis of the chromatinafter different sonication 
times. Blue rectangle indicates chromatin fragments. (C) Analysis of endogenous RBPJ binding to the 
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Hes1 proximal promoter region by ChIP-qPCR, using chromatin extracted from MEFs derived from E12.5 
mice wild-type. Analysis of the chromatin was made with (+) and without (-) antibody against RBPJ. Two 
negative control regions within open reading frames (ORFs) were tested (ORF2-Dll1; ORF3-Fbxw7). 
Mean ± SD of triplicate assays are shown. 
2.2. Comparing MyT1L and MyT1 activities in the Hes1 proximal promoter 
region 
MyT1 is a zinc-finger transcription factor paralog to MyT1L. Work in our laboratory found 
that MyT1 strongly represses the Notch activation of the Hes1 proximal promoter.  In order to 
compare the ability of MyT1L and MyT1 to inhibit the Hes1 proximal promoter, I performed a 
RGA where different ratios of transcription factors and NICD were used. Since NICD is more 
efficient than aN1 in activating the Hes1 proximal promoter, I chose to use this vector. As 
expected, NICD upregulates the Hes1 promoter by 60-fold (Figure 9). In contrast, when cells 
also express MyT1L or MyT1 the NICD-dependent activity of the Hes1 promoter activation is 
strongly reduced at all tested ratios (Figure 9). 
The results suggest a redundant function between MyT1L and MyT1 in counteracting Notch 
activity in the Hes1 proximal promoter. Interestingly, MyT1L repression was more efficient 
when competing with higher concentrations of NICD, suggesting a stronger affinity to the Hes1 
proximal promoter region. 
 
 
 
 
 
 
 
 
Figure 8 – MyT1L-HA downregulates the Notch activated Hes1 proximal promoter. (A) Scheme 
depicting the pCAG-MyT1L-HA plasmid sub-cloning. Black rectangle indicates the amplified fragment 
from the MyT1L wild type. (B) Analysis of protein size of MyT1L-HA expressed from two distinct clones 
of pCAG-MyT1L-HA (1-2) by Western blot. (C) Reporter gene assays in P19 cells co-transfected with 
control, Activated Notch (aN1), MyT1L and/or MyT1L-HA expression vectors and a reporter construct 
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expressing luciferase under the control of Hes1 proximal promoter region. Mean ± SD of triplicate assays 
are shown. 
2.3. MyT1L binds the Hes1 proximal promoter region in MEFs 
Sequence analysis of the Hes1 proximal promoter showed the existence of three MyT1 
binding sites (Figure 2B). In fact, previous work in our laboratory demonstrated that MyT1 
directly binds to the MyT1 binding sites region of the Hes1 proximal promoter in NS/PCs. Since 
MyT1L is structurally similar to MyT1 and given the previous results with RGAs, one could 
expect that MyT1L also binds to the same region of the Hes1 proximal promoter when 
ectopically expressed in MEFs. To verify this I performed a ChIP-qPCR against MyT1L-HA. 
Chromatin was extracted from MEF cultures expressing MyT1L-HA upon lentiviral delivery. The 
chromatin extraction protocol was previously optimized in order to have a maximum of 
number of MEFs expressing MyT1L-HA with the minimum addition of lentivirus. The protocol 
was downscaled from 3x T150 flasks to a T25 flask. Optimization of the protocol demonstrated 
that extracted chromatin from a T25 flask was equally sonicated as the chromatin extracted 
from T75 and T150 flasks (Figure 10A).    
 
 
 
 
 
 
 
 
 
Figure 9 – MyT1L and MyT1 counter act Notch activation of Hes1 proximal promoter. Reporter gene 
assays in P19 cells co-transfected with control, Notch Intracellular Domain (NICD), MyT1 and/or MyT1L-
HA expression vectors and a reporter construct expressing luciferase under the control of Hes1 proximal 
promoter region. The different NICD:MyT1 or NICD:MyT1L-HA are depicted in the figure. Mean ± SD of 
triplicate assays are shown. 
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Cultured MEFs were infected with a mix of lentiviruses combining a MyT1L-HA with the 
reverse tetracycline transactivator (rtTA). The MyT1L-HA lentivirus encapsulates the TetON-
FUW-Myt1L-HA construct sub-cloned from the previously generated pCAG-Myt1L-HA plasmid. 
The expression of MyT1L-HA was induced by the addition of Doxycycline (DOX) (Figure 10B) 
and chromatin extracted two days after the induction (Figure 10C). The ChIP-qPCR was 
performed with a ChIP grade antibody direct against the HA tag. MEFs infected with MyT1L-HA 
show strong enrichment of MyT1L-HA in the Hes1 promoter region, as compared with two 
negative control regions (Figure 10D). The same was not observed in uninfected MEFs. 
Additionally, MyT1L-HA binding was also detected at a regulatory region in the vicinity of the 
Notch1 gene. Previous work in our laboratory showed binding by MyT1 in this regulatory 
region of the Notch1 gene in NS/PCs.  
Overall, these results show that MyT1L can bind to the Hes1 promoter region in MEFs two 
days after being ectopically expressed suggesting a potential role for MyT1L in regulation of 
Hes1 expression in MEFs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – MyT1L binds to the Hes1 and Notch1 proximal promoter regions. (A) Analysis of the 
chromatin fragments size after 14 minutes sonication by electrophoresis. Chromatin was extracted from 
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MEFs cultured in T25, T75 or T150 flasks. Blue rectangle indicates chromatin fragments. (B) Scheme 
depicting the experiment in which MEFs infected with TetON-FUW MyT1L-HA were induced by DOX and 
harvested for chromatin extraction and ChIP.  (C) Chromatin fragment size analysis by electrophoresis 
after 14 minutes sonication of the chromatin previously extracted. The chromatin was extracted from 
MEFs culture in T25 flasks. Blue rectangle indicates chromatin fragments. (D) Analysis of MyT1L-HA 
binding in the Hes1 proximal promoter region and Notch1 promoter region by ChIP-qPCR in chromatin 
extracted from MEFs wild-type (without lentivirus infection) and MEFs MyT1L-HA (with Myt1L-HA 
lentivirus infection). Both chromatins were tested with and without anti-HA tag. Two negative control 
regions within open reading frames (ORFs) were tested (ORF1-Hes1; ORF3-Fbxw7). Mean ± SD of 
triplicate assays are shown. 
3. Establishment of a method to reprogram fibroblasts 
into induced Neurons (iN cells) 
3.1. Optimization of the lentiviral infection protocol 
In order to establish a reprogramming protocol to convert MEFs into iN cells, it is necessary 
to first optimize the efficiency of lentiviral infection in this cell type. I determined the optimal 
amount of Polybrene, a polymer that enhances the ability of the virus to infect, at three 
different concentrations, 1, 4 and 8 µg/mL. Polybrene was added to a lentivirus mix containing 
the vectors for V5-Ascl1, rtTA and GFP (A-1F Mix) (Figure 11A) in MEF cultures. After DOX 
induction during two days, immunocytochemistry was performed against the V5 tag. The 
number of V5+ cells increases with the increase of polybrene concentration (Figure 11B, C). 
Infected MEFs with no induction were used as a control. 
Following the previous result, the minimum volume of virus stock needed to have high 
infection levels and low cell death was tested. The experiment included conditions with 
different volumes (2.5, 10, 15, 20 µL) for the A-1F Mix and the 1F Mix with the MyT1L-HA 
lentivirus (M-1F Mix) (Figure 12A). The infection was performed with 8µg/mL of Polybrene. 
MEFs were infected with Empty, rtTA and GFP lentivirus (Control Mix) to control for lentivirus 
infection effects in MEFs. The results show a maximum of cell infection from both factors 
around the 10%-12% (Figure 12C, E). The minimum volume to reach this value for MyT1L-HA 
lentivirus is 10 µL. V5-Ascl1 lentivirus produces the same maximum percentage of cell infection 
that is observed with MyT1L-HA infection.  No increase was observed when further increasing 
the viral volume (15 or 20 µL, Figure 12B, D). It was not possible to obtain data for the 10 µL 
V5-Ascl1 lentivirus infection due to loss of sample. 
The addition of 8µg/mL of Polybrene and 10 µL of virus from each factor results in an 
infection rate of ≈10% of the cells in culture. Although low, this can still be considered a 
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significant rate of infection and these conditions were therefore used in the subsequent 
experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 – Higher concentrations of polybrene correlate with higher infection rate. (A) Scheme 
depicting experiment in which MEFs were infected with V5-Ascl1 inducible lentiviruses with different 
concentration of polybrene. Infection rate was assessed by expression of V5-Ascl1 induced after 
addition of DOX. (B) Analysis by immunocytochemistry for the V5-tag upon infection with V5-Ascl1 
expressing lentivirus with different concentration of polybrene (0,1 , 2, 4 and 8µg/mL) 2 days after 
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addition of DOX. Control MEFs were infected with Ascl1-V5 lentivirus but were not induced. Scale bar: 
50 µm. (C) Histogram represents the percentage of MEFs infected with V5-Ascl1 lentivirus (V5+/DAPI) 
with each concentration of polybrene. Data presented as the mean ± SD for 10 randomly selected fields 
for each condition. 
3.2. Ascl1 and Ascl1/MyT1L-dependent reprogramming of MEFs 
It has been previously demonstrated that the ectopic expression of Ascl1 in MEFs is sufficient 
to promote neuronal reprogramming of these cells, even in the absence of other known 
reprogramming factors (Chanda et al., 2014; Vierbuchen et al., 2010). I therefore applied a 
single-factor reprogramming protocol with Ascl1 expression to our MEFs in the optimized 
conditions described above. MEFs cultures were therefore infected with the A-1F Mix or the 
Control Mix.  One day after infection V5-Ascl1 expression was induced with DOX. Cells were 
transferred two days later to neuronal differentiating medium (N3 medium). Cultures were 
then collected for immunostaining against Tuj1 at 7, 14 and 21 days post-induction 
(Figure13A).  At 7 days post-induction, some of the cells expressing V5-Ascl1 also express Tuj1, 
whilst none of the control cells show Tuj1 staining (Figure 13B). The percentage of Tuj1+ cells 
was approximately 3% (Figure 13C), an efficiency considerably lower than the one that has 
been reported in the literature (Chanda et al., 2014; Vierbuchen et al., 2010). Also, the 
observed Tuj1+ cells display an immature morphology and lacked neurites or extensions.  It 
was no possible to observe reprogrammed cells in cultures from 14 days post-induction and 
onwards as these did not survive the long incubation periods. 
Since the combination of Ascl1 with MyT1L has been shown to be more effective than 
single-factor reprogramming in MEFs, I proceed to co-infect the cells with lentivirus mix 
combining V5-Ascl1, rtTA, and either MyT1L-HA (HA-2F MIX) or MyT1L-WT (WT-2F Mix).Cells 
were also infected with A-1F Mix. In order to increase the survival rate observed 7 days post-
induction in N3, this neuronal differentiating medium was substituted by the N2B27 medium. 
Induction and change of medium were performed at the same time points described above. 
Cells were collected for immunostaining against Tuj1 7 to 14 days-post induction (Figure 14A). 
At 7 days post-induction, some of the cells expressing V5-Ascl1, and V5-Ascl1 with MyT1L-HA 
or –WT also expressed Tuj1, whereas none of the control cells (infected with Control Mix) 
show Tuj1 staining (Figure 14B). The percentage of Tuj1+ cells from the cultures infected with 
A-1F Mix was approximately 3.5% (Figure 14C). The percentage of Tuj1+ cells for cultures with 
HA- and WT-2F Mix was 1% and 2.5% respectively. Samples infected with the 2F Mix presented 
a much higher rate of cell death (Figure 14C) than observed in other conditions. As in the 
previous experiment, the immature morphology of Tuj1+ cells indicates either premature cell 
death or a delayed development into mature neurons (Figure 14B). 
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Figure 12 – Higher amount of virus result in higher infection rates but not above ≈12%. (A) Scheme 
depicting experiment in which MEFs were infected with V5-Ascl1 and MyT1L-HA inducible lentiviruses 
with different volumes from virus stock. Infection rate was assessed by expression of V5-Ascl1 and 
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MyT1L-HA induced after addition of DOX. (B, D) Analysis by immunocytochemistry for the anti-V5 tag 
and anti-HA tag upon infection with different volumes of V5-Ascl1, MyT1L-HA and Empty lentivirus 
(Control) stock. MEFs cultures were collected for analysis 2 days after induction with DOX. Scale bar: 50 
µm. (C, E) Histogram represents the percentage of MEFs infected with V5-Ascl1 lentivirus (V5+/DAPI), 
MyT1L-HA lentivirus (HA+/DAPI) and Control, for each volume of lentivirus stock. Data presented as the 
mean ± SD for 10 randomly selected fields for each condition. 
The alteration of neuronal differentiating medium did successfully prolong the survival of 
cells beyond 7 days post-induction, but did not increase significantly the percentage of Tuj1+ 
cells. No Tuj1+ cells were found at 14 day post-induction, and very few cells remained alive at 
this time point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 – MEFs reprogramming to iN cells with overexpression of Ascl1. (A) Scheme illustrating the 
experiment in which MEFs were reprogrammed to iN cells by infection with V5-Ascl1 inducible 
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lentivirus.  (B) Immunocytochemical analysis for the neuronal marker Tuj1 upon infection with V5-Ascl1 
lentivirus or Empty lentivirus (Control) 7 days post induction. White arrows indicate the Tuj1+ cells. Scale 
bar: 50 µm. (C) Histogram represents the percentage of Tuj1+ cells (Tuj1+/DAPI) 7 days post-induction of 
V5-Ascl1 expression in MEFs infected with V5-Ascl1 (“+”) or Empty (“-”) lentiviruses. Data presented as 
the mean ± SD for 10 randomly selected fields for each condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 – MEFs reprogramming to iN cells with overexpression of Ascl1 and Ascl1 plus MyT1L-
WT/HA. (A) Scheme illustrating the experiment in which MEFs were reprogrammed to iN cells by 
infection with V5-Ascl1 inducible lentivirus alone or in combination with MyT1L-WT/HA inducible 
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lentiviruses. (B) Immunocytochemical analysis for Tuj1 upon infection with V5-Ascl1 lentivirus without 
and with MyT1L-HA or MyT1L-WT 7 days post induction. Empty lentivirus infection was used as control. 
White arrows indicate the Tuj1+ cells. Scale bar: 50 µm. (C) Histogram represents the percentage of 
Tuj1+ cells (Tuj1+/DAPI) 7 days post-induction of V5-Ascl1 expression alone or in combination with 
MyT1L-WT/HA expression in MEFs. Data presented as the mean ± SD for 30 consecutive fields for each 
condition. † represents the rate of cell death. 
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Discussion 
MyT1L was described to have a late function in Ascl1-dependent reprogramming, mainly 
driving the maturation process of iN cells, increasing their morphological complexity and their 
electrophysiological properties (Pang et al., 2011; Pfisterer et al., 2011; Vierbuchen et al., 
2010). The work here shows that ectopically expressed MyT1L can bind to DNA in MEFs as 
early as 2 days after MyT1L induction. Specifically, it is shown that MyT1L can bind to the 
proximal promoter of Hes1 and repress its activity. This suggests that one of the roles of 
MyT1L in Ascl1-dependent reprogramming of MEFs into neurons is the transcriptional 
derepression of Ascl1 targets via inhibition of endogenous Hes1 expression.  
Although a couple of previous studies have implicated Notch signalling in the promotion of 
cell cycle arrest and apoptosis of MEFs (Ishikawa et al., 2008; Liu et al., 2012), it is still unclear 
to which extent the endogenous Notch pathway is active in this cellular context. To assess the 
level of activity of Notch signalling in MEFs, I measured the levels of expression of its 
downstream targets, Hes1 and Hes5. Surprisingly, the expression of Hes1 in MEFs is at the 
same order of magnitude of the levels measured for culture NS/PCs, which display high levels 
of Notch activity. However, treatment with the γ-secretase does not affect Hes1 expression, 
suggesting that the Notch pathway is not the main regulator of Hes1 expression in MEFs. The 
Hes5 promoter is often used as a reporter of Notch signalling in vivo where its expression 
levels are often considered a readout of Notch activation (Basak and Taylor, 2007; Lugert et al., 
2010). In contrast to Hes1, the expression of Hes5 is found at very low levels in MEFs when 
compared to those found for in cultured NS/PCs. Overall, this suggests that Notch signalling is 
not strongly active in MEFs. 
Hes1 is regulated by the Notch effector RBPJ in NS/PCs (Iso et al., 2003; Louvi and 
Artavanis-Tsakonas, 2006). Sequence analysis of Hes1 proximal promoter region shows the 
presence of three RBPJ binding sites (Figure 2B) (Iso et al., 2003). I observed RBPJ enrichment 
in the RBPJ binding sites region of the Hes1 promoter in MEFs. RBPJ regulation is dependent of 
Notch activity, as it needs the interaction with the cleaved Notch receptor, NICD, to form an 
activator complex. On the other hand, when Notch activity is low RBPJ acts as a repressor 
(Castel et al., 2013). Since the results suggest low activity of Notch signalling, RBPJ may be 
acting as a repressor in MEFs. I show that Hes1 is highly expressed in MEFs, suggesting that 
RBPJ repression of Hes1 in these cells may be in competition with activating mechanisms 
which are independent of Notch activity. In mouse fibroblasts, Hes1 expression is known to be 
controlled by other pathways independent of Notch activity. Such pathways include the Sonic-
Hedgehog pathway and the JAK-STAT signalling pathway (Ingram et al., 2008; Yoshiura et al., 
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2007). The Sonic-Hedgehog regulation of Hes1 was shown to be independent of γ-secretase-
mediated Notch cleavage (Ingram et al., 2008). Since the transcription factor Hes1 regulates 
negatively its own expression, stabilization of Hes1 protein by inhibition of JAK-STAT signalling 
results in a sustained expression of Hes1 (Yoshiura et al., 2007).  Moreover, in human intestinal 
tumorigenesis, the Wnt/β-catenin signalling was shown to up-regulate Hes1 expression 
independently of Notch activity (Peignon et al., 2011). This study showed that the Wnt/β-
catenin signalling directly controls the activity of the Hes1 promoter through the interaction 
with the Wnt/β-catenin effector, Tcf. Importantly, the two Tcf binding sites found for the 
human Hes1 promoter are conserved in the mouse genome (Peignon et al., 2011), strongly 
suggesting that Wnt/β-catenin signalling may be regulating Hes1 expression also in mice.  
Work from our laboratory found that MyT1, a paralog transcription factor to MyT1L, is able 
to counteract the activation by Notch of the Hes1 proximal promoter region. Sequence 
analysis of the Hes1 proximal promoter shows the existence of three MyT1 binding sites 
(AAGTT), which coincide with the Hes1 promoter region with high enrichment for MyT1 (Figure 
2B). I performed a comparative transcriptional assay between MyT1L and MyT1 that shows 
similar reduction of the activity of the Hes1 proximal promoter, although with slightly higher 
efficiency for MyT1L.  This is in line with previous studies, showing that MyT1L displays a 
higher affinity to the AAGTT motif comparatively to MyT1 (Besold et al., 2010; Gamsjaeger et 
al., 2008). 
Ascl1-dependent reprogramming of MEFs to iN cells is controlled by Ascl1 due to its 
function as an “on-target” pioneer factor (Wapinski et al., 2013). This means that Ascl1 is able 
to target its bona fide target genes, independently of their chromatin accessibility in MEFs. 
Work in our laboratory also described that Hes1 acts as a transcriptional repressor of Ascl1 
target genes in cultured NS/PCs. One interesting possibility is that Hes1 can repress the 
expression of Ascl1 target genes during neuronal reprogramming of MEFs. This repression may 
be the reason why iN cells have low levels of maturity observed in Ascl1 single-reprogramming 
(Chanda et al., 2014; Vierbuchen et al., 2010). MyT1L has been described to have a role at late 
stages of reprogramming by increasing the maturity of iN cells (Ambasudhan et al., 2011; Pang 
et al., 2011; Vierbuchen et al., 2010; Yoo et al., 2011). However, MyT1L ability to bind to its 
target genes in MEFs was still to be determined.  I demonstrate through ChIP-qPCR that MyT1L 
binds to the Hes1 proximal promoter in MEFs, two days after MyT1L induction. This suggests 
Hes1 as a possible target of MyT1L in reprogramming. Future experiments should demonstrate 
that MyT1L is able to downregulate the endogenous expression of Hes1 in MEFs. Moreover, I 
show in the same ChIP-qPCR experiment that Myt1L binds to a regulatory region of Notch1, 
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indicating Notch1 as another target gene of MyT1L in MEFs. This suggests that MyT1L can bind 
to its available targets in MEFs at early stages of reprogramming. 
During neurogenesis MyT1 competes with the RBPJ for their respective binding sites in the 
Hes1 proximal promoter region to regulate Hes1 expression (Figure 2). In MEFs, I did not found 
evidence for Notch regulation of Hes1. Therefore, RBPJ does not activate the Hes1 promoter 
by forming the RBPJ-NICD activator complex. This suggests that repression of Hes1 by MyT1L is 
not a result of the competition between MyT1L and the RBPJ-NICD activator complex, like 
MyT1 repression of Hes1 in NS/PCs (Figure 15A). Thus, MyT1L repression of Hes1 expression in 
MEFs would likely require direct repression activity at the Hes1 promoter (Figure 15B). In 
support of this idea, MyT1 and MyT1L were shown to interact with Sin3B (Romm et al., 2005), 
a protein that mediates transcriptional repression by binding to histone deacetylases (HDACs) 
(Wolffe et al., 2000). Future experiments should demonstrate how MyT1L represses its target 
genes in MEFs reprogramming into iN cells (Figure 15B). 
In reprogramming, MyT1L may indirectly promote the activation of Ascl1 target genes, and 
contributing to the maturation of neurons, by downregulating the expression of Hes1 (Figure 
15C). In order to explore this hypothesis with Hes1 gain-of- and loss-of-function studies, I 
attempted at establishing a protocol to reprogram MEFs into neurons. However, this purpose 
was not achieved, mainly due to the high cell death rate 7 days post-induction. High cell death 
in neuronal reprogramming protocols is not exclusive to this study. Future experiments should 
therefore include some alterations to the protocol. Per example, high cell death was 
successfully  overcome by the addition of the anti-apoptotic gene BCL2L1 to reprogrammed 
neurons culture (Victor et al., 2014). Alternatively, co-culture with glia cells was also shown to 
extend the culture of Ascl1 single-reprogrammed iN cells by 2 weeks (Chanda et al., 2014). In 
addition, the rate of infection could be improved by adjusting the ratios of the various viruses. 
Finally, optimization of the lentivirus production to increase virus titter could be another 
solution towards an improved protocol. 
MyT1L binds to the Hes1 proximal promoter in MEFs 2 days after MyT1L induction, 
suggesting a role at early stages of reprogramming. This may lead to promoting iN cell 
maturation by counteracting Hes1 inhibition of Ascl1 target genes (Figure 15C).  In addition, 
MyT1L was also shown to bind to the Notch1 regulatory region in MEFs. Further studies should 
look at a genome-wide approach to identify other MyT1L targets that could be important for 
the reprogramming process. Finally, MyT1L downregulation of Hes1 in MEFs still needs to be 
assessed, as well as the importance of Hes1 regulation during reprogramming. Studies that 
look at the effects of gain-of- and loss-of-function of Hes1 during reprogramming and 
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identifying its targets in MEFs in a genome-wide level could shed a new light into the role of 
Hes1 in the reprogramming process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 – Model of MyT1L repression of Hes1 in MEFs and MyT1L function in Ascl1-dependent 
reprogramming of MEFs into iN cells. (A) Scheme depicting the model of MyT1 repression of the Hes1 
expression at the Hes1 proximal promoter. In neural stem/progenitor cells (NS/PCs) the MyT1 
repression of Hes1 expression results from the competition between MyT1 and RBPJ for their respective 
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target sites in the Hes1 promoter. RBPJ is promoting Hes1 expression by interacting with the Notch 
intracellular domain (NICD) and forming the RBPJ-NICD activator complex. (B) In MEFs, I hypothesize 
that MyT1L repression of Hes1 occurs not by competing with the RBPJ-NICD activator complex but by 
direct repression activity at the Hes1 promoter through the recruitment of transcriptional repressors. 
(C) Ascl1 can reprogram MEFs into iN cells but with low levels of maturity (low morphological complexity 
and electrophysiological properties). Addition of MyT1L in combination with Ascl1 results in iN cells with 
higher levels of maturation. One possibility is that MyT1L indirectly promotes the expression of Ascl1 
target genes responsible for neuronal maturation. 
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